Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of dapagliflozin on exercise capacity in HFpEF
jRCT2080224652Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Exercise capacity (likely change in 6-minute walk distance). Started Apr 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2080224652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224652.